Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 22

Trial Status

Recruiting1
Other1

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT05136196Phase 2Recruiting
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more
PrincipalinvestigatorStart date: 2022-12-06
NCT02965716Phase 2Active Not Recruiting
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Advanced MelanomaRecurrent MelanomaStage III Cutaneous Melanoma AJCC v7+5 more
PrincipalinvestigatorStart date: 2018-06-05

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Rodabe N Amaria

M.D. Anderson Cancer Center

Related
6 trials

Shared therapeutic areas:

Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7+3 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Aung Naing, Md

M.D. Anderson Cancer Center

Related
16 trials

Shared therapeutic areas:

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Siqing Fu, MD, PhD

M.D. Anderson Cancer Center

Related
6 trials

Shared therapeutic areas:

Advanced MelanomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8
Similarity Score3%

Vincent Chung

City of Hope Medical Center

Related
9 trials

Shared therapeutic areas:

Metastatic MelanomaUnresectable Melanoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Melanoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Jun Guo, MD

Peking University Cancer Hospital & Institute

Related
13 trials

Shared therapeutic areas:

Advanced MelanomaMetastatic Melanoma
Similarity Score2%

James C Yang, M.D.

National Cancer Institute (NCI)

Related
7 trials

Shared therapeutic areas:

Metastatic Melanoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

loic MONDOLONI

Assistance Publique Hopitaux De Marseille

Related
28 trials

Shared therapeutic areas:

Metastatic Melanoma
Similarity Score1%

Wenyin Shi, MD, PhD

Thomas Jefferson University

Related
5 trials

Shared therapeutic areas:

Recurrent Melanoma
Similarity Score1%

Harriet Kluger, MD

Yale University

Related
5 trials

Shared therapeutic areas:

Advanced Melanoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT05136196Phase 2PrincipalInvestigator

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more
Recruiting
NCT02965716Phase 2PrincipalInvestigator

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Advanced MelanomaRecurrent MelanomaStage III Cutaneous Melanoma AJCC v7+5 more
Active Not Recruiting

All 2 trials loaded